The clinical significance of incidental soft tissue uptake on whole body 18F-sodium fluoride bone PET-CT

被引：5
作者：
Usmani, S. [1 ]
Gnanasegaran, G. [2 ]
Marafi, F. [3 ]
Esmail, A. [3 ]
Ahmed, N. [4 ]
Van den Wyngaert, T. [5 ]
机构：
[1] Kuwait Canc Control Ctr, Dept Nucl Med, POB 1488, Khaitan 83001, Kuwait
[2] Royal Free Hosp NHS Trust, London, England
[3] Jaber Al Ahmad Mol Imaging Ctr, Kuwait, Kuwait
[4] Castle Hill Hosp, Jack Brignall PET CT Ctr, Cottingham, England
[5] Antwerp Univ Hosp, Antwerp, Belgium
来源：
CLINICAL RADIOLOGY | 2019年 / 74卷 / 02期
关键词：
POSITRON-EMISSION-TOMOGRAPHY; F-18-NAF PET/CT; F-18-FLUORIDE PET; VASCULAR CALCIFICATION; UNEXPECTED DETECTION; HEPATIC METASTASES; TRACER UPTAKE; PATIENT; TC-99M-MDP; OSTEOSARCOMA;
D O I：
10.1016/j.crad.2018.09.007
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
F-18-sodium fluoride (NaF) is a PET bone imaging agent and is commonly used in imaging patients with cancer; however, similar to technetium-99m medronic acid (Tc-99m-MDP), it can be useful in the evaluation of benign bone and joint conditions. NaF is an excellent bone-seeking agent with high bone uptake due to rapid single-pass extraction. It has negligible plasma protein binding, rapid blood, renal clearance, high bone uptake and almost all NaF delivered is retained by bone after a single pass of blood; however, uptake of NaF can be observed in non-osseous structures such as the arterial vasculature, gastrointestinal tract, genitourinary tract, and viscera. In this article, we present a spectrum of clinical cases with non-osseous NaF uptake in patients referred for cancer staging. (C) 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：95 / 110
页数：16
相关论文
共 50 条
[1]   Salt in the wound: F-18-fluoride positron emission tomography for identification of vulnerable coronary plaques [J].
Adamson, Philip D. ;
Vesey, Alex T. ;
Joshi, Nik V. ;
Newby, David E. ;
Dweck, Marc R. .
CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2015, 5 (02) :150-155
[2]   F-18 Fluoride Uptake in Calcified Extraosseous Metastases From Ovarian Papillary Serous Adenocarcinoma [J].
Agrawal, Kanhaiyalal ;
Bhattacharya, Anish ;
Harisankar, Chidambaram Natarajan Balasubramanian ;
Abrar, Mohammed Labeeb ;
Dhaliwal, Lakhbir Kaur ;
Mittal, Bhagwant Rai .
CLINICAL NUCLEAR MEDICINE, 2012, 37 (01) :E22-E23
[3]   Microcalcified Hepatic Metastases Incidentally Detected on F-18 NaF PET/CT in a Patient with Prostate Cancer [J].
Aktas G.E. ;
Sarıkaya A. ;
Can N. ;
Demir S.S. .
Nuclear Medicine and Molecular Imaging, 2017, 51 (4) :364-367
[4]  
[Anonymous], ANN ICRP, V38, P1
[5]   Unexpected Diffuse 18F-NaF Uptake in the Lung Parenchyma in a Patient With Severe Hypercalcemia Due to Myelomatosis [J].
Asmar, Ali ;
Simonsen, Lene ;
Svolgaard, Birgitte ;
Bulow, Jens .
CLINICAL NUCLEAR MEDICINE, 2017, 42 (01) :68-69
[6]   Serendipitous Observation of Hepatic Metastases on 18F-Fluoride PET in a Patient with Infiltrating Ductal Carcinoma of Breast Correlation With Contrast Enhanced CT [J].
Basu, Sandip ;
Kembhavi, Seema .
CLINICAL NUCLEAR MEDICINE, 2012, 37 (12) :1176-1178
[7]   18F-NaF PET/CT: EANM procedure guidelines for bone imaging [J].
Beheshti, M. ;
Mottaghy, F. M. ;
Payche, F. ;
Behrendt, F. F. F. ;
Van den Wyngaert, T. ;
Fogelman, I. ;
Strobel, K. ;
Celli, M. ;
Fanti, S. ;
Giammarile, F. ;
Krause, B. ;
Langsteger, W. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (11) :1767-1777
[8]   Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate [J].
Blake, GM ;
Park-Holohan, SJ ;
Cook, GJR ;
Fogelman, I .
SEMINARS IN NUCLEAR MEDICINE, 2001, 31 (01) :28-49
[9]   Incidental Detection of Solitary Hepatic Metastasis by 99mTc-MDP and 18F-NaF PET/CT in a Patient With Osteosarcoma of the Tibia [J].
Cai, Liang ;
Chen, Yue ;
Huang, Zhanwen ;
Wu, Jingbo .
CLINICAL NUCLEAR MEDICINE, 2015, 40 (09) :759-761
[10]   Intense 99mTc-MDP and 18F-NaF Activity in Long-standing Subcutaneous Implants [J].
Chen, Li ;
Chen, Yue ;
Huang, Zhanwen ;
Cai, Liang ;
Huang, He .
CLINICAL NUCLEAR MEDICINE, 2016, 41 (10) :812-814
12345